Novo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise




The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger. Read More


Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *